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Abstract
The present review evaluates the role of sleep and its alteration in triggering problems of glucose metabolism and the possible 
involvement of adipokines in this process. A reduction in the amount of time spent sleeping has become an endemic condition 
in modern society, and a search of the current literature has found important associations between sleep loss and alterations 
of nutritional and metabolic contexts. Studies suggest that sleep loss is associated with problems in glucose metabolism and a 
higher risk for the development of insulin resistance and type 2 diabetes mellitus. The mechanism involved may be associated 
with the decreased efficacy of regulation of the hypothalamus-pituitary-adrenal axis by negative feedback mechanisms in sleep-
deprivation conditions. In addition, changes in the circadian pattern of growth hormone (GH) secretion might also contribute to 
the alterations in glucose regulation observed during sleep loss. On the other hand, sleep deprivation stress affects adipokines 
- increasing tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and decreasing leptin and adiponectin -, thus establishing 
a possible association between sleep-debt, adipokines and glucose metabolism. Thus, a modified release of adipokines result-
ing from sleep deprivation could lead to a chronic sub-inflammatory state that could play a central role in the development of 
insulin resistance and type 2 diabetes mellitus. Further studies are necessary to investigate the role of sleep loss in adipokine 
release and its relationship with glucose metabolism.
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Sleep loss due to voluntary bedtime restriction has be-
come common in recent years, produced by the demands 
and opportunities of modern society (1). Sleep-deprivation 
can be total, when no sleep is allowed, or partial, when the 
retiring time is delayed or the rising time is advanced. In the 
United States, the proportion of young adults with a period 
of sleep shorter than 7 h a day has increased from 15.6% 
in 1960 to 37.1% in 2001-2002 (2). In Brazil, sleep habits 
of the adult population in the city of São Paulo, estimated 
in surveys carried out in 1987 and 1995, have shown a 
slight, but significant, change behavior during this time. 
Total hours slept varied from 7:45 to 9:00 h in 1987 to 7:40 
to 8:40 h in 1995. There was also a significant decrease in 
total hours slept during the weekends in 1995 compared 
to 1987 (3). 
Recent studies have described a significant impairment 
of glucose control in individuals who have decreased sleep 
duration (1,4,5); in addition, these subjects are more sus-
ceptible to metabolic problems such as insulin resistance 
(1,5) and type 2 diabetes mellitus (DM2) (6-9).
The mechanism involved in impaired glucose metabo-
lism following changes in the sleep-wake rhythm seems to 
be a decreased efficacy of the negative-feedback regulation 
of the hypothalamus-pituitary-adrenal (HPA) axis (1). Recent 
studies have indicated that adipokines may be implicated 
in these alterations (10,11). This article discusses the 
influence of sleep and sleep loss on the development of 
insulin resistance and DM2, and the mechanisms involved 
in this process. 
Review protocol 
A computer-based search of the literature indexed 
in MEDLINE was made using the key words: glucose 
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metabolism, insulin resistance, adipokines, adiponectin, 
interleukin-6 (IL-6), leptin, tumor necrosis factor-alpha 
(TNF-α), sleep deprivation, and sleep loss. Studies that 
have measured the relationship between sleep duration 
and glucose metabolism are discussed in the first part of 
the article; in the second, the relationships between the 
adipokines/sleep loss and changes in glucose metabolism 
are considered. Studies that evaluated alterations in adi-
pokines and in glucose metabolism as a consequence of 
sleep apnea have been excluded.
Type 2 diabetes mellitus and sleep duration
Several studies have examined the association between 
sleep duration, sleep disturbance, and the development 
of DM2. Analysis of cross-sectional data from the Sleep 
Heart Health Study revealed that reduced sleep duration 
was associated with an increased prevalence of insulin 
resistance and DM2, after controlling for sleep-disordered 
breathing, a condition that may independently influence 
glucose control (12). Trenell et al. (9) found a U-shaped 
relationship between sleep duration and the incidence 
of DM2, as did Ayas et al. (6), Chaput et al. (13), and 
Yaggi et al. (14). In this last prospective-cohort study (14), 
middle-aged and elderly men reporting short sleep duration 
(≤5:00 or 6:00 h of sleep per night) were twice as likely to 
develop DM2 as those reporting >8:00 h of sleep per night. 
Similarly, those who reported long sleep duration (>8:00 
h of sleep per night) were more than three times as likely 
to develop DM2 over the follow-up period, confirming the 
U-shaped relationship between sleep duration and DM2. 
The elevated risk remained essentially unchanged after 
adjustment for age, hypertension, smoking status, self-
rated health status, education, and waist circumference 
(RR = 1.95 [95%CI = 0.95-4.01] for ≤5 or 6 h and RR = 
3.12 [95%CI = 1.53-6.37] for >8 h). 
Cappuccio el al. (15) conducted a meta-analysis to as-
sess the relationship between habitual sleep disturbances 
and the incidence of DM2 and to obtain an estimate of the 
risk. Ten studies (13 independent cohort samples; 107,756 
male and female participants, follow-up range 4.2-32 years, 
and 3586 incident cases of DM2) were included. In the 
analysis stratified by gender, no differences were detected 
between short duration of sleep or difficulty in maintaining 
sleep and the development of DM2. 
There is insufficient evidence regarding the effect of 
gender on the relationship between sleep duration and DM2 
(16,17). Most of the evidence that does exist has come from 
samples composed of both genders or of females only. A 
prospective study conducted by Mallon et al. (8) followed 
a random sample of 1170 subjects aged 45-65 years and 
initially free of DM2, for 12 years. Men (N = 550) who had 
developed DM2 at follow-up more often reported short 
sleep duration (≤5 h per night) (16.0 vs 5.9%, P < 0.01), 
difficulties initiating sleep (16.0 vs 3.1%, P < 0.001), and 
difficulties maintaining sleep (28.0 vs 6.3%, P < 0.001) than 
did those who did not develop DM2. However, short or long 
sleep durations or sleep complaints did not influence the 
risk of new cases of DM2 among women (N = 620). 
Tuomilehto et al. (18) examined the association be-
tween sleep duration and DM2 and abnormal glucose 
tolerance among 1336 men and 1434 women, aged 45-
74, who participated in a survey over a 2-year period. In 
contrast to the study cited previously, these investigators 
found that short (6 h) or long (8 h) sleep duration was re-
lated to an increased risk of DM2 in middle-aged women, 
but not in men. Also, Ayas et al. (6), who studied a cohort 
of 70,026 women enrolled in the Nurses Health Study, 
found an increased risk of incidence of symptomatic DM2 
over 10 years among those reporting sleep durations of 5 
h or less compared to those who slept 7-8 h. These results 
were obtained after numerous covariates were controlled 
(hypercholesterolemia, hypertension, smoking, snoring, 
exercise, alcohol, depression, postmenopausal hormone 
use, and family history of DM2) (18). 
The failure to detect any association between sleep 
duration and diabetes in men may be due to the fact that 
men are known to have a higher overall incidence of 
sleep-disordered breathing with obstructive sleep apnea 
than women, and this may be one major reason for their 
disturbed sleep patterns (18). Testosterone levels can also 
mediate the effects of both short and long sleep duration 
on DM2 risk, and could presumably explain the difference 
between genders in this aspect. Yaggi et al (14), in the 
same study cited earlier, pointed out that RRs were altered 
considerably for the two extreme sleep groups (≤5 and >8 
h of sleep per night) when adjusted for testosterone (1.51 
[0.71-3.19] for ≤5 h and 2.81 [1.34-5.90] for >8 h), suggest-
ing that the effects of sleep on diabetes could be mediated 
via changes in endogenous testosterone levels. Previous 
studies have shown that low levels of testosterone have 
been associated with risk factors for diabetes (19) and 
elevated levels of insulin and glucose (20,21). Low levels 
of testosterone have been related to diabetes in cohort 
studies (21). In clinical studies, administration of testos-
terone to obese men improved insulin sensitivity (22) and, 
conversely, insulin is also thought to regulate testosterone 
(23). In addition, previous studies have also linked sleep 
disruption to reduced testosterone levels (24).
There is some evidence of a U-shape relationship 
between sleep duration and DM2, demonstrating that ex-
tremes of sleep time in either direction may be associated 
with this important disease. In addition, researches have 
shown an important association between short sleep dura-
tion and the development of DM2 in both genders, although 
some studies suggest that the relationship is stronger in 
women. Anyway, we can infer that the differences between 
genders has not yet been demonstrated conclusively and 
further studies are needed for this hypothesis to be actu-
ally confirmed.
994 H.G. Padilha et al.
www.bjournal.com.brBraz J Med Biol Res 44(10) 2011
Insulin resistance, glucose tolerance and 
sleep loss
In healthy individuals, plasma glucose homeostasis 
results from a tightly controlled balance between glucose 
delivery (from the gut in the post-prandial state and from 
the liver in the post-absorptive state) and glucose utiliza-
tion. Insulin plays a key role in this process, by inhibiting 
hepatic glucose production and by stimulating glucose 
uptake in insulin-sensitive tissues (mainly skeletal muscle 
and adipose tissue) (1). Insulin resistance is defined as a 
state where a normal or elevated insulin level produces an 
attenuated biological response; classically, such a state 
refers to impaired sensitivity to insulin-mediated glucose 
disposal (1). β-cells can compensate for a small degree of 
insulin resistance but the hyperglycemic state occurs when 
β-cell function is unable to be sufficiently up-regulated, and 
so DM2 develops (25). 
Spiegel et al. (5) analyzed glucose tolerance in 11 
young men after time in bed had been restricted to 4 h per 
night for 6 nights (sleep-debt condition). The investigators 
compared this condition with measurements taken at the 
end of a sleep-recovery period (fully rested condition), when 
participants had been allowed 12 h per night in bed for 6 
nights. Investigators found that glucose effectiveness, which 
quantifies the ability of glucose to mediate its own disposal 
independently of insulin, was 30% lower in the sleep-debt 
condition than after the sleep-recovery condition (1.7 vs 
2.6%/min, P < 0.0005). The investigators pointed out that 
this difference in glucose effectiveness was nearly identical 
to that reported between groups of patients with non-insulin-
dependent diabetes and normoglycemic white men (1.4 vs 
2.6%/min) (26). In addition, the acute insulin response to 
glucose was 30% lower in the sleep-debt condition than 
in the sleep-recovery condition (304 vs 432 pmol/min, P 
< 0.04). This evidence indicates an important impairment 
of glucose metabolism due to acute total sleep restriction; 
therefore, the possibility exists that sleep loss may result in 
long-term adverse effects on glucose tolerance. 
In another study, Van Cauter et al. (4) investigated the 
roles of circadian rhythmicity (intrinsic effects of time of 
day independent of the sleep or wake condition) and sleep 
(intrinsic effects of the sleep condition, irrespective of the 
time of day) on the 24-h variation in glucose tolerance. The 
study included eight healthy men and the investigators 
analyzed glucose and insulin secretion rates during 8 h of 
nocturnal sleep followed by 28 h of wakefulness and 8 h of 
daytime sleep. To avoid confounding effects of prolonged 
fasting or meal ingestion, intravenous glucose was infused 
at a constant rate throughout the study period without wak-
ing the subjects. During nocturnal sleep, glucose levels 
and insulin secretion increased by 31 ± 5 and 60 ± 11%, 
respectively, and returned to baseline in the morning. Dur-
ing sleep deprivation, glucose levels and insulin secretion 
rose to a maximum at a time corresponding to the begin-
ning of the habitual sleep period. However, the magnitude 
of this circadian rise was roughly half the amplitude of the 
rise seen during nocturnal sleep (16.6 ± 4.7% for glucose 
and 49.3 ± 7.6% for insulin secretion). Daytime sleep was 
associated with a rise above pre-sleep levels of 16.3 ± 3.4 
and 54.6 ± 7.1% in glucose levels and insulin secretion, 
respectively. The investigators also demonstrated that the 
profiles of insulin concentrations paralleled those of glucose 
and insulin secretory rates during nocturnal sleep and during 
daytime sleep but a nocturnal acrophase in the absence 
of sleep was detected in only 4 of the 8 subjects. This lack 
of parallelism between the profiles of insulin secretion and 
peripheral insulin concentrations during sleep deprivation 
reflected a circadian variation in insulin clearance, with 
clearance rates 30-40% higher during the first half of the 
habitual sleep period (23:00-3:00; 1.57 ± 0.20 L/min) than 
in the morning (8:00-11:00; 1.16 ± 0.13 L/min, P < 0.01). 
These findings are consistent with the concept that both 
circadian rhythmicity and sleep modulate glucose levels, 
insulin secretion and insulin clearance (4). 
Considering the longer-term effects of sleep deprivation, 
Mander et al. (27) studied 27 non-obese patients who were 
either chronic short sleepers (sleeping <6.5 h on weekdays), 
or normal sleepers (sleeping 7.5-8.5 h). Sleep diaries were 
confirmed by wrist actigraphy for 8 consecutive nights. On 
the last 2 days of the study, patients were submitted to 
a glucose tolerance test. Both groups had normal basal 
glucose levels, but short sleepers had significantly higher 
levels of basal C peptide - a marker of insulin secretion. 
The insulin sensitivity of these short sleepers was also 40% 
lower than normal. This suggests that metabolic responses 
might change when sleep debt becomes chronic. If this is 
the case, then it has been argued that the initial impairment 
of glucose tolerance and of the responsiveness of β-cells 
might, if extended, foster the subsequent development of 
insulin resistance (25).
Roles of counter-regulatory hormones, cortisol  
and growth hormone, in the changes in glucose  
metabolism observed during conditions of sleep loss
Disturbances in the secretory profiles of the counter-
regulatory hormones, cortisol and growth hormone (GH), 
may also contribute to the alterations in glucose regulation 
observed during sleep loss (28).
Cortisol has an immediate effect on the secretion of insu-
lin, inducing inhibition in the absence of changes in glucose 
concentration (29). After partial and total sleep deprivation, 
plasma cortisol levels were significantly higher during the 
night in young men who had been sleep-deprived (37 and 
45% increases, P = 0.03 and 0.003, respectively) (30). 
This metabolic response may reflect a decreased efficacy 
of the negative-feedback regulation of the HPA axis (31). 
Simulating a sleep-debt condition, Spiegel et al. (5) analyzed 
11 young men whose time in bed had been restricted to 4 
h per night for 6 nights. Compared to the sleep-recovery 
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condition, sleep debt was associated with alterations in the 
24-h profile of plasma cortisol, including a shorter quiescent 
period (537 vs 634 min, P < 0.03), largely due to a delay 
in its onset of nearly 1.5 h (at 19:30 [47 min] vs 17:01 h 
[43], P < 0.04). In addition, the activity of the sympathetic 
nervous system, measured by heart rate variability, was 
also increased (P < 0.02). It is possible that these changes 
are linked and reflect the fact that sleep deprivation leads 
to stress and over-stimulation of the sympathetic system, 
with a consequent increase in cortisol secretion. 
Disorders in the profile of GH secretion might also 
contribute to the alterations in glucose regulation ob-
served during sleep loss. GH is secreted in a series of 
pulses throughout the 24-h cycle, with greater changes in 
concentration due to more frequent and larger secretory 
pulses taking place during sleep (32). In normal adults, peak 
plasma concentrations of GH occur during the first half of 
sleep (33,34). The rapid anti-insulin-like effects of the GH 
released during sleep (32) are responsible for reducing 
glucose uptake by peripheral tissues (1). 
Plat et al. (31) showed that sleep restriction was as-
sociated with a longer elevation of GH during the night. 
Spiegel et al. (28) evaluated the effects of semi-chronic 
partial sleep loss on the 24-h GH profile in 11 young men. 
The sleep-loss protocol consisted of 16 consecutive nights 
in a Clinical Research Center: 3 nights with 8 h in bed from 
23:00 to 7:00 h; 6 nights with time in bed limited to a 4-h 
period from 1:00 to 5:00 h, and 7 nights with 12 h in bed 
from 21:00 to 9:00 h. Unexpectedly, after 1 week of bedtimes 
reduced to 4 h, all subjects exhibited a GH pulse before 
sleep onset and this pre-sleep onset pulse was the largest 
secretory episode of the 24-h cycle for 5 of the subjects. 
As a result, the mean 24-h profiles of plasma GH and GH 
secretory rates during the state of sleep debt exhibited a 
biphasic pattern of nocturnal release, with a large pulse 
occurring during waking (at around the usual time of sleep 
onset on a standard 8-h bedtime schedule) followed by a 
second pulse after the onset of restricted sleep. The biphasic 
nature of the GH secretory pattern during sleep restriction 
resulted in a longer duration of exposure of peripheral 
tissues to elevated GH concentrations (>4 µg/L) during 
sleep extension (252 ± 25 vs 205 ± 33 min, P = 0.02). This 
secretory pattern contrasts with the mean profiles during 
sleep extension that present the usual single nocturnal GH 
pulse early in sleep. These findings of an extended time 
of exposure of peripheral tissues to higher GH levels are 
potentially important in subjects who are sleep deprived, 
because such changed levels are related to adverse effects 
with regard to glucose regulation.
Roles of adipokines and sleep loss in the changes in 
glucose metabolism
In recent years, it has been recognized that white adi-
pose tissue is not just an energy-storage organ, but also an 
active participant in energy homeostasis and physiological 
functions such as immunity and inflammation (35). Adipose 
tissue functions as an endocrine organ and secretes a num-
ber of bioactive peptides and proteins, collectively termed 
“adipokines”, including leptin, adiponectin and resistin, as 
well as cytokines, such as TNF-α and IL-6 (36). 
Much evidence produced during the past decade has 
shown that the release of adipokines by either adipocytes 
or adipose tissue-infiltrated macrophages leads to a chronic 
sub-inflammatory state that could play a central role in 
the development of disorders of glucose metabolism (36). 
Moreover, it has been shown that adipokines such as TNF-α, 
IL-6, and C-reactive protein (CRP) are present at increased 
concentrations in individuals who are insulin-resistant and 
obese, and these biomarkers predict the development of 
DM2 (37). Also, stress due to sleep deprivation affects 
inflammatory markers, linking sleep-debt, adipokines and 
insulin resistance (38).
TNF-α
TNF-α is a cytokine that is expressed by macrophage 
and other cell types and whose expression is up-regulated 
in adipose tissue and/or skeletal muscle of obese, insulin-
resistant humans and animals (39). Some evidence from 
the literature has suggested that TNF-α can be considered 
to be a molecular link between obesity and insulin resis-
tance (39). 
A number of studies have demonstrated that TNF-α 
alters the insulin-signaling pathway in cultured cells in 
vivo. Anti-TNF-α antibodies ameliorate insulin sensitivity in 
obese rodents, and TNF-α-deficient mice are protected from 
obesity-induced insulin resistance when living on a high-fat 
diet (38). Currently, however, the molecular mechanism 
whereby TNF-α attenuates the insulin-signaling pathway 
is not well understood. Potential mechanisms by which 
adipose tissue TNF-α could increase insulin resistance 
include increased release of free fatty acid (FFA) by adipo-
cytes, reduction of adiponectin synthesis, and impairment 
of insulin signaling (39).
In humans, the soluble receptor for TNF-α is a normal 
constituent of cerebrospinal fluid and inhibits sleep (11). 
This receptor also reduces the increase in non-rapid eye 
movement (nonREM) sleep (mainly stages 3 and 4) that 
normally occurs after sleep deprivation (40). These findings 
provide very strong evidence supporting the hypothesis that 
TNF-α plays a key role in sleep homeostasis (41).
In humans, sleep loss also affects the TNF-α system. 
In a study of mild sleep loss (2 h per night for 7 nights) in 
healthy men (N = 12) and women (N = 13), sleep restriction 
was associated with a significant increase (post-minus pre-
sleep restriction) in the overall 24 h TNF secretion cycle in 
men (0.26 ± 0.1 pg/mL; P < 0.01), but not in women (-0.06 
± 0.03; P = NS) (11). Thus, in men, the increase in TNF-α 
following sleep deprivation might lead to impaired glucose 
metabolism.
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IL-6
IL-6 is a pro-inflammatory cytokine shown to modify 
insulin sensitivity (42). Al-Khalili et al. (43) reported that 
IL-6 directly enhances glucose uptake and metabolism and 
increases insulin sensitivity in cultured myotubes prepared 
from human skeletal muscle biopsies. Signaling pathways 
via AMP-activated protein kinase (AMPK) (44) and phos-
phatidylinositol 3-kinase (43) have been implicated in the 
effects of IL-6 on glucose metabolism in cultured cells.
Of the adipokines, IL-6 has been shown to have the 
strongest correlation with insulin resistance and associated 
complications (42). Plasma levels of IL-6 are 2-3 times 
higher in patients with obesity and DM2 than in lean control 
subjects. This elevation is strongly related to increased 
blood glucose, decreased glucose tolerance, and decreased 
insulin sensitivity (42). 
Vgontzas et al. (45) have shown that total sleep loss 
is associated with an increased secretion of IL-6. A more 
recent study from the same group (11), using a modest 
daily restriction of sleep by 2 h/night for 1 week in young 
healthy men and women, found that the mean concentration 
of IL-6 over a 24-h period was significantly increased (by 
0.8 ± 0.3 pg/mL; P < 0.05) in both genders. On the other 
hand, Frey et al. (46), obtained different results when they 
studied 19 healthy men and women aged 28.05 ± 8.56 
(mean ± SD) in a condition of total sleep deprivation (40 
h under constant routine conditions). Repeated-measures 
ANOVA with planned comparisons showed that acute total 
sleep deprivation induced a significant decrease in IL-6 
levels (main effect of sleep deprivation F(1,18) = 4.774, P 
< 0.05). Taken together, these findings suggest that one 
night of sleep loss triggers a stress response that includes 
stimulation of pro-inflammatory proteins in healthy young 
subjects (47). Because IL-6 is produced by many cells in 
the periphery, including endothelial cells, factors that affect 
the activation of these cells - for example, vasoconstriction 
and blood pressure -, are likely to be important determinants 
of the response to sleep loss (47). This suggests that mild 
sleep loss may also be associated with long-term risks of 
DM2.
Leptin
Leptin is an amino acid secreted by adipocytes in pro-
portion to their total tissue mass. This hormone provides 
the appetite-regulating center in the brain with information 
about energy balance, and its release is associated with the 
promotion of satiety (48). Margetic et al. (49) suggested a 
peripheral interaction of leptin with insulin, mobilizing fuels 
and inhibiting energy storage mechanisms. Also, insulin has 
been shown to increase leptin production (48). 
Although the principal biological effect of leptin in the 
central nervous system is the control of food intake and en-
ergy expenditure, in obesity there is a significant relationship 
between leptinemia and a chronic sub-inflammatory state. 
This relationship suggests other, possibly peripheral, bio-
logical effects associated with the cytokine-like structure of 
leptin (48). Indeed, an increased pro-inflammatory response 
has been observed in hyperleptinemia (50). Although the 
mechanisms accounting for this association have not been 
clearly identified, leptin is capable of increasing TNF-α 
production and macrophage activation (51). 
On the other hand, accumulating evidence suggests 
that leptin promotes fatty acid oxidation and reduces fat 
accumulation in non-adipose tissues, thereby increasing 
insulin sensitivity. This effect is directly mediated by leptin by 
activation of the AMPK acting on certain skeletal muscles, 
and also indirectly through the hypothalamic-sympathetic 
nervous system axis (52). As a result of AMPK activation, 
the enzyme acetyl coenzyme A (CoA) carboxylase is inhib-
ited, leading to reduced intracellular levels of the metabolite 
malonyl CoA. This alleviates the inhibition of fatty acid entry 
into the mitochondria and favors fatty acid oxidation (52), 
demonstrating the close relationship between leptin and 
lipid metabolism.
Both chronic partial sleep deprivation (53) and acute 
sleep deprivation (54) cause a reduction in the serum con-
centration of leptin. Spiegel et al. (54) evaluated the pattern 
of leptin secretion in 11 males subjected to a shortened 
sleep time (4 h) for 6 nights. Mean and maximum leptin 
values were lower (by 19 and 26%, respectively) during 
sleep restriction, compared to the same individuals when 
they had slept for a normal period of time (8 h). This result 
suggests that sleep plays an important role in promoting 
leptin secretion. In a cross-sectional study carried out with 
1024 volunteers, Taheri et al. (55) also observed that short 
sleep was associated with low leptin levels, with a decrease 
of 15.5% occurring when subjects who habitually slept for 8 
h were compared with those who habitually slept for 5 h. 
An effect of sleep duration on leptin levels could also 
reflect the impact of hormones that interact with leptin and 
are also modulated by sleep. Conversely, sleep-dependent 
alterations of leptin may result in alterations of leptin-
sensitive hormonal axes (54). Indeed, most prominent 
among the hormonal systems that interact with leptin as 
well as with sleep regulation are the HPA axis and glucose 
regulation by insulin.
Adiponectin
Adiponectin is a protein that is produced predominantly 
by adipocytes and has been shown to have anti-diabetic, 
anti-atherogenic, and anti-inflammatory properties (56). 
Like leptin, adiponectin enhances insulin sensitivity through 
activation of AMPK (57). Adiponectin also decreases hepatic 
glucose production by decreasing the mRNA expression 
of two essential enzymes involved in gluconeogenesis: 
phosphoenolpyruvate carboxykinase and glucose-6-phos-
phatase (56). Clinical and experimental observations 
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indicate that low plasma levels of adiponectin contribute to 
the pathogenesis of insulin resistance and DM2 in obese 
or overweight patients (57). 
Also, adiponectin can reduce the inflammatory response 
induced by TNF-α, as shown by in vitro studies where 
macrophage activity and TNF-α production were dimin-
ished after treatment with adiponectin (56). Ablation of the 
adiponectin gene had no obvious metabolic effects in mice 
fed a chow diet; however, when they were fed a high fat/
sucrose diet, the knock-out mice developed severe insulin 
resistance accompanied by increased lipid deposition in 
muscle. Adipose tissue and plasma TNF-α levels were 
increased as a result of adiponectin deficiency, and these 
changes were reversed by adiponectin treatment (58). It 
appears that many of the anti-inflammatory properties of 
adiponectin arise from its anti-TNF-α effects. 
Sleep loss leads to a decrease of adiponectin levels. Ko-
tani et al. (59) measured fasting serum adiponectin levels in 
109 healthy Japanese males who had regular lifestyles. Each 
subject’s lifestyle was assessed by the self-administered 
Breslow Questionnaire (a well-established method to iden-
tify various lifestyles). Partial correlation analysis for serum 
adiponectin levels, after controlling for age and other lifestyle 
factors, revealed a significant negative correlation between 
serum adiponectin levels and body mass index (BMI; r = 
-0.222, P = 0.025), and a significant positive correlation 
between serum adiponectin levels and sleep duration (r = 
0.252, P = 0.011). No significant correlations were observed 
between adiponectin and other lifestyle factors. These data 
suggest that increased BMI and shorter sleep duration might, 
via the associated low serum adiponectin levels, act as risk 
factors for insulin resistance and DM2.
Further studies are required to understand how 
adipokines are involved in glucose metabolism and the 
mechanisms by which sleep seems to play an important 
role in their release. Such an understanding would add to 
knowledge about some of the factors that alter glucose 
metabolism. 
Conclusions
There are many studies showing that sleep loss con-
tributes to the onset of insulin resistance and DM2. The 
mechanisms involved in the impaired glucose metabolism 
seem to act via a decreased efficacy of the HPA axis 
and GH secretion. In addition, the modified release of 
adipokines - especially IL-6, TNF-α and adiponectin - dur-
ing stress and following disturbances of the sleep pattern 
leads to a systemic chronic sub-inflammatory state in the 
adipose tissue that could play a central role in the devel-
opment of insulin resistance and DM2. However, further 
studies are necessary to better elucidate the role of sleep 
loss in adipokine release and its relationship with glucose 
metabolism, which could be important to avoid the increased 
prevalence of DM2 in populations chronically exposed to 
sleep loss, such as shift workers. This is an exciting new 
field of study, and elucidation of the mechanisms involved 
might have profound implications for an understanding of 
these disorders and for public health. 
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